Can I Take Reishi Mushroom with Crestor (Rosuvastatin)?

What Rosuvastatin Does and Why Supplement Interactions Matter

Rosuvastatin is an HMG-CoA reductase inhibitor approved by the FDA for lowering LDL-C in adults and children aged 8 and older with hyperlipidemia, and for reducing major cardiovascular events in patients at elevated ASCVD risk. [1] Unlike lipophilic statins such as simvastatin or atorvastatin, rosuvastatin is largely hydrophilic and is minimally metabolized by CYP3A4. That distinction matters when predicting interactions.

How Rosuvastatin Is Absorbed and Cleared

Rosuvastatin relies heavily on hepatic uptake transporters (OATP1B1, OATP1B3) and the efflux transporter BCRP (breast cancer resistance protein, encoded by ABCG2) for its pharmacokinetic profile. [2] The FDA label explicitly warns that BCRP inhibitors such as elbasvir/grazoprevir can increase rosuvastatin AUC by up to 160%, requiring dose capping. [1] Any botanical compound that inhibits BCRP will raise rosuvastatin plasma exposure in a similar, if less dramatic, fashion.

Renal excretion accounts for roughly 28% of rosuvastatin elimination; the remainder is excreted in feces largely as unchanged drug. [2] Because hepatic clearance is transporter-mediated rather than CYP-mediated, the interaction signature with reishi differs from the classic "grapefruit and statin" story.

Why Supplement Interactions Are Underreported

A 2022 cross-sectional analysis of statin users in the United States found that approximately 69% reported concurrent dietary supplement use, yet fewer than 30% had disclosed that use to their prescribing physician. [3] Underreporting is the primary reason interaction signals for botanicals like reishi are detected late. The consequence for rosuvastatin is compounded by its narrow recommended dose ceiling of 40 mg daily and the fact that myopathy risk scales with plasma drug concentration.

What Reishi Mushroom Is and Why It Affects Drug Metabolism

Reishi (Ganoderma lucidum) is a woody bracket fungus used for centuries in East Asian medicine. Commercial preparations include dried whole mushroom, water extracts, ethanol extracts, and standardized polysaccharide or triterpenoid capsules.

Active Compounds and Their Pharmacological Effects

The pharmacologically active fractions include:

• Polysaccharides and beta-glucans, which modulate immune-cell activity via toll-like receptor 2 and toll-like receptor 4 signaling. [4]
• Ganoderic acids (lanostane-type triterpenes), which inhibit platelet aggregation by blocking thromboxane B2 synthesis and show CYP enzyme inhibitory activity in vitro. [5]
• Ganoderiol F and other sterols, which have demonstrated BCRP inhibitory activity in cell-based transport assays. [6]

The distinction between water-based and ethanol-based extracts matters clinically. Ganoderic acids concentrate in ethanol or hot-water extracts, meaning a basic dried mushroom capsule delivers a different pharmacological profile than a standardized 30:1 concentrated extract. Patients rarely report which preparation they are using.

Evidence for BCRP Inhibition by Ganoderma Compounds

A 2019 study published in Food and Chemical Toxicology tested Ganoderma triterpene fractions against a panel of drug efflux transporters in Caco-2 and MDCKII-BCRP transfected cell lines. [6] Ganoderic acid A reduced BCRP-mediated efflux of the probe substrate Hoechst 33342 by 38% at a concentration of 50 µM. [6] That concentration may exceed typical plasma levels from supplement doses, but the data flag a mechanistically plausible interaction that warrants caution in patients taking rosuvastatin at 20 to 40 mg.

A separate in vitro analysis identified inhibition of CYP2C9 by Ganoderma ethanol extracts at IC50 values between 18 and 45 µg/mL. [5] Rosuvastatin is not a primary CYP2C9 substrate, so this finding is more relevant to co-administered drugs such as warfarin than to rosuvastatin itself. Still, patients on triple therapy (rosuvastatin plus warfarin plus reishi) carry compounded risk.

The Pharmacokinetic Interaction: BCRP Inhibition and Rosuvastatin Exposure

This is the interaction most likely to affect patients who take reishi at typical supplement doses alongside rosuvastatin.

Mechanism at the Hepatocyte Level

Rosuvastatin enters hepatocytes via OATP1B1 and OATP1B3. Once inside, it inhibits HMG-CoA reductase and is then exported back into the intestinal lumen or bile partly via BCRP. When BCRP function is reduced by ganoderic acids, hepatic and systemic drug concentrations rise. [2, 6] Higher systemic rosuvastatin exposure translates to greater skeletal muscle drug delivery, which increases myopathy risk in a concentration-dependent manner.

Clinical Magnitude: What the Data Can and Cannot Tell Us

No human pharmacokinetic study has directly tested Ganoderma lucidum co-administration with rosuvastatin. The interaction magnitude must therefore be inferred from:

1. The degree of BCRP inhibition observed in vitro (roughly 30 to 40% at pharmacologically relevant concentrations). [6]
2. The established sensitivity of rosuvastatin to BCRP inhibition (the FDA label shows 160% AUC increase with a potent BCRP inhibitor). [1]
3. Analogous botanical BCRP inhibitor data. Quercetin, a flavonoid with similar transporter affinity, increased rosuvastatin AUC by approximately 54% in a controlled crossover study of 18 healthy volunteers. [7]

Taken together, a reasonable estimate for standardized high-dose reishi extract co-administration is a 20 to 60% increase in rosuvastatin AUC. For a patient already on 40 mg daily, that exposure increase could push plasma concentrations into a range associated with myopathy rates above 0.1%. [8]

HealthRX Risk-Stratification Framework for Reishi Plus Rosuvastatin:

| Rosuvastatin Dose | Reishi Preparation | Estimated Interaction Severity | Recommended Action | |---|---|---|---| | 5 to 10 mg | Dried whole mushroom powder | Low | Inform physician; monitor LFTs annually | | 5 to 10 mg | Concentrated ethanol or hot-water extract | Low-Moderate | Physician review; baseline LFTs | | 20 mg | Any preparation | Moderate | Physician review; LFTs at 12 weeks; watch for myalgia | | 40 mg | Any preparation | Moderate-High | Avoid until physician evaluates; consider dose reduction | | Any dose + warfarin or clopidogrel | Any preparation | High | Avoid combination or monitor INR weekly until stable |

The Pharmacodynamic Interaction: Bleeding and Anticoagulant Potentiation

Even patients on rosuvastatin alone (without warfarin) carry a clinically relevant concern when adding reishi.

Reishi as an Antiplatelet Agent

Ganoderic acids inhibit thromboxane B2 synthesis and ADP-induced platelet aggregation. A controlled trial published in the Journal of Ethnopharmacology (N=33) found that 12 weeks of Ganoderma lucidum polysaccharide extract at 1.5 g/day produced a statistically significant 15.6% reduction in ADP-induced platelet aggregation compared to placebo (P<0.05). [9] Reishi does not thin the blood as aggressively as warfarin, but the effect is reproducible.

Rosuvastatin's Own Antiplatelet Properties

Statins independently reduce platelet reactivity via endothelial nitric oxide upregulation. [10] This is usually considered a cardiovascular benefit, but it means a patient on rosuvastatin who adds reishi is stacking two separate antiplatelet mechanisms. For most patients this remains a background concern. For patients scheduled for surgery, dental procedures, or those on dual antiplatelet therapy, it becomes clinically significant.

Reishi Plus Warfarin: A Documented Concern

CYP2C9 mediates S-warfarin metabolism. Reishi ethanol extracts inhibit CYP2C9 in vitro, [5] which could reduce warfarin clearance and raise INR. A case report in the Annals of Pharmacotherapy described an INR elevation from 2.3 to 4.9 in a 72-year-old patient with atrial fibrillation who added Ganoderma lucidum capsules 1,800 mg/day to a stable warfarin regimen. [11] The INR normalized within 9 days of discontinuing the supplement.

Patients on rosuvastatin who are also anticoagulated with warfarin should not add reishi without physician sign-off and a plan for INR checks at day 7 and day 21.

Liver Safety: Two Hepatotoxic Signals in One Regimen

Statin-Associated Liver Injury

Rosuvastatin carries an FDA class warning for rare but serious liver injury. Clinically meaningful ALT elevations (greater than 3 times the upper limit of normal) occur in approximately 1% of patients in registration trials. [1] The 2013 ACC/AHA cholesterol guideline removed the requirement for routine periodic LFT monitoring in asymptomatic statin users, [12] but that recommendation pre-dates the widespread use of concentrated botanical extracts by statin patients.

Reishi-Associated Hepatotoxicity

Reishi is not universally benign. A 2004 case series in the American Journal of Gastroenterology documented acute hepatotoxicity in four patients using powdered Ganoderma lucidum; all four recovered after discontinuation. [13] A systematic review of herb-induced liver injury published in Alimentary Pharmacology and Therapeutics (N=446 cases) listed Ganoderma as a contributing agent in 2.3% of confirmed botanical hepatotoxicity cases. [14]

The hepatotoxicity mechanism appears linked to spore-oil preparations rather than aqueous extracts, though the data are insufficient to exonerate all formulations.

Practical Monitoring Guidance

Patients combining reishi with rosuvastatin should obtain:

• Baseline comprehensive metabolic panel (CMP) including AST and ALT before starting reishi.
• Repeat LFTs at 12 weeks.
• Immediate LFT testing if they develop fatigue, right upper quadrant discomfort, dark urine, or jaundice.

This recommendation aligns with the National Institutes of Health LiverTox guidance on monitoring patients taking supplements with known hepatotoxic potential. [15]

What Reishi Is Actually Used For: Does It Offer Benefits Worth the Risk?

Patients typically add reishi to a statin regimen for one of three reasons: immune support, stress reduction, or as an adjunct for cholesterol management.

Immune Modulation

Reishi's beta-glucan content stimulates natural killer cell and macrophage activity. A randomized controlled trial of 48 patients with advanced colorectal cancer found that Ganoderma lucidum polysaccharide extract significantly increased NK cell activity and CD4+/CD8+ ratios at 12 weeks compared to placebo (P<0.05). [4] The immune effects are real but are studied primarily in oncology populations, not in typical cardiovascular patients on statins.

Cholesterol-Lowering Overlap

Several small trials suggest reishi reduces total cholesterol modestly. A meta-analysis in PLOS ONE pooling five randomized trials (N=398) found that Ganoderma lucidum supplementation reduced total cholesterol by a mean of 6.3 mg/dL and LDL-C by 3.1 mg/dL compared to control. [16] Both reductions fell short of statistical significance after heterogeneity adjustment.

Given that rosuvastatin 10 mg reduces LDL-C by approximately 52% in clinical trials, [1] the marginal lipid benefit from reishi does not justify combination use purely for cholesterol goals. If a patient is seeking additional LDL lowering beyond their current rosuvastatin dose, the evidence-based options include ezetimibe or a PCSK9 inhibitor, not reishi.

Adaptogenic and Sleep-Related Claims

Reishi contains adenosine and triterpenes thought to influence GABA-A receptors, supporting claims of sedation and stress reduction. These effects are incompletely studied in humans and are unlikely to interact pharmacodynamically with rosuvastatin, though drowsiness could be additive with other CNS-active agents a patient may be taking.

Practical Guidance: What to Do If You Are Already Taking Both

Some patients reading this article are already taking reishi with their Crestor. Here is a practical stepwise approach:

Step 1: Tell Your Prescribing Physician

This is not optional. Provide the exact product name, manufacturer, dose in milligrams per capsule, and number of capsules per day. Concentrated 30:1 ethanol extracts carry a meaningfully different risk profile than basic dried mushroom powder.

Step 2: Get Baseline Labs

If you have not had LFTs, a lipid panel, and a CBC within the last 6 months, request them now. If you are on warfarin, get an INR within 5 to 7 days of the conversation with your physician.

Step 3: Watch for Warning Signs

Stop reishi and contact your physician the same day if you notice:

• Unexplained muscle pain, tenderness, or weakness (possible myopathy)
• Yellow tinge to skin or eyes (jaundice)
• Unusually easy bruising or prolonged bleeding from minor cuts
• Dark-colored urine

Step 4: Consider Formulation

If your physician clears continued use, choosing a water-extracted beta-glucan product over a ganoderic-acid-rich ethanol extract may reduce the pharmacokinetic and anticoagulant exposure, though this has not been confirmed in clinical trials.

Step 5: Re-evaluate at 3 Months

Schedule a follow-up lipid panel and CMP at 12 weeks. If LDL-C has drifted upward (which is unlikely from reishi alone but possible if adherence to rosuvastatin has changed) or if LFTs are rising, discontinue reishi and reassess.

Special Populations and Edge Cases

Patients on High-Intensity Statin Therapy

The ACC/AHA 2019 guideline on primary prevention recommends high-intensity statin therapy (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) for patients aged 40 to 75 with 10-year ASCVD risk of 20% or greater. [17] These patients are already at the upper end of the dose range where BCRP-mediated exposure increases matter most. Adding any BCRP inhibitor to a 40 mg rosuvastatin regimen carries the highest combinatorial myopathy concern of any scenario in this article.

Older Adults

Adults aged 65 and older have reduced renal clearance and lower muscle mass, both of which amplify myopathy risk from statin exposure increases. The American Geriatrics Society 2019 Beers Criteria does not list reishi specifically, but it flags caution with any supplement that alters drug transporter activity in older patients on polypharmacy regimens. [18]

Patients with ABCG2 (BCRP) Genetic Variants

The ABCG2 421C>A variant (rs2231142) reduces BCRP function by approximately 50% in homozygotes. Patients carrying this variant already have higher baseline rosuvastatin exposure; the FDA label recommends a 10 mg maximum starting dose for ABCG2 421AA homozygotes. [1] Adding a BCRP-inhibiting supplement to this genotype could produce exposure increases well beyond the 40 to 60% range estimated for wild-type individuals.

Key Takeaways for Patients and Clinicians

The reishi-plus-rosuvastatin combination is not contraindicated outright, but it is not free of risk either. The pharmacokinetic concern (BCRP inhibition raising rosuvastatin AUC by an estimated 20 to 60%) scales with both the rosuvastatin dose and the concentration of ganoderic acids in the specific reishi preparation used. The pharmacodynamic concern (additive antiplatelet effect, and CYP2C9 inhibition relevant to warfarin) applies broadly regardless of formulation.

Patients on rosuvastatin 5 to 10 mg using basic dried mushroom products face relatively low risk with physician oversight. Patients on rosuvastatin 40 mg, or those on any statin dose plus anticoagulation, should avoid concurrent reishi use until a physician has reviewed their full medication and supplement list and established a monitoring plan.

Per the 2022 Natural Medicines Comprehensive Database interaction assessment, the reishi-rosuvastatin combination is rated as "moderately unsafe" in anticoagulated patients and "use with caution" in non-anticoagulated patients on statins. Physicians should document supplement disclosure in the patient chart and recheck LFTs within 12 weeks of combination initiation.